INTRODUCTION

Triple-negative breast cancer is a subtype of highly malignant breast cancer, which is prone to distant metastasis and has a poor prognosis.1 Tumor metastasis involves multiple steps including tumor cell detachment from the primary tumor, invasion through the extracellular matrix, penetration of blood vessels, interaction with circulating tumor cells with vascular endothelium, and extravasation into and invasion of the target organ.2 In addition, tumor angiogenesis not only plays an important role in tumor growth, but is an essential step for tumor metastasis. A high degree of tumor vascularization increases the chance for cancer cells to reach the bloodstream, and newly formed blood vessels are more permeable to cancer cells, which also promotes tumor metastasis.3

Abbreviations: ATP, adenosine triphosphate; Ca-CM, cancer cell conditioned medium; CCN2, cellular communication network factor 2; CTGF, connective tissue growth factor; ECs, endothelial cells; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; NC, Negative Control; OS, overall survival; TNBC, triple-negative breast cancer.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
The tumor microenvironment is characterized by an unusually high concentration of adenosine triphosphate (ATP). When tumor tissue, especially fast growing tumor tissue, is in a hypoxic and ischemic condition, ATP is released from cells undergoing necrosis, apoptosis, and autophagy, and extracellular ATP could reach several hundred micromoles. Extracellular ATP mediates a wide range of biological functions in tumors, such as stimulating tumor cell proliferation, migration, and invasion into the tumor microenvironment. Extracellular ATP can also modulate EC migration and angiogenesis, and increase the adhesion of polymorphonuclear granulocytes to ECs. Previous research has demonstrated that hypoxia can induce angiogenesis and cancer cell adhesion to ECs. Whether extracellular ATP could stimulate cancer cell adhesion to ECs remained to be investigated.

Connective tissue growth factor (CTGF), also known as cellular communication network factor 2 (CCN2), is one of the most widely studied members of the CCN family. CTGF is highly expressed in many cancer types, including breast cancer, pancreatic cancer, glioma, etc., and plays an important role in tumor cell proliferation, migration, invasion, and metastasis. CTGF could promote cell proliferation by regulating cell cycle-related proteins in TNBC cells, and promote bone metastasis of breast cancer through the integrin αvβ3-ERK1/2 signaling pathway. CTGF could also promote the epithelial–mesenchymal transition (EMT) of tumor cells, and chemotherapeutic resistance. In addition to its direct effect on tumor cells, CTGF causes the fibrosis and inflammatory microenvironment of tumors, and induces angiogenesis through paracrine or autocrine pathways, which further supports its promotion of tumor progression.

To reveal the molecular mechanism behind extracellular ATP stimulation of tumor invasion and metastasis, we used cDNA microarray and RNA-seq to identify differentially expressed genes in breast cancer cells MCF-7 and fibroblast cells HFF1, before and after 100 μM ATP treatment. We found that CTGF mRNA was upregulated in HFF1 and RNA-seq analysis verified this finding in TNBC cells. qRT-PCR confirmed this finding in TNBC cells, fibroblast cells HFF1, and human ECs HUVECs. Through functional tests, we found that ATP could promote angiogenesis and TNBC cell adhesion to ECs. We hypothesized that CTGF exerted a stimulating effect on ATP-driven angiogenesis and TNBC cell adhesion to the endothelium.

2 | MATERIALS AND METHODS

2.1 | Cell lines and culture

MDA-MB-231, SK-BR-3, and MCF10A cells were purchased from ATCC. MCF-7, HS578T, and EA.hy926 cells were bought from the Cell Resource Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. HUVEC and HMEC-1 cells were bought from Zhong Qiao Xin Zhou Biotechnology. HUVEC and HMEC-1 cells were cultured in endothelial culture medium (ECM) bought from Zhong Qiao Xin Zhou Biotechnology. MCF-7, SK-BR-3, MDA-MB-231, HS578T, and EA.hy926 cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) (GIBCO).

2.2 | Statistical analysis

All the experiments were performed in triplicate. All the data were analyzed using Prism 6 (GraphPad Software). Student’s t test was used to determine the difference between each two groups. Error bars in the experiments indicated standard deviation (SD). Any values of \( p < 0.05 \) were considered statistically significant.

Details of additional methodologies can be found in Appendix S1.

3 | RESULTS

3.1 | ATP induces ECs migration, angiogenesis, and cancer cell adhesion to ECs in vitro

Our previous research works demonstrated that ATP promotes BC cell invasion and metastasis. We wondered whether extracellular ATP could affect EC migration, angiogenesis, and cancer cell adhesion to ECs. As shown in Figure S1, ATP dramatically promoted the migration of ECs EA.hy926 and HMEC-1 in wound healing assays. Transwell migration assays demonstrated that 100 μM ATP was most effective in enhancing migration (Figures 1A and S1B) of ECs (HUVECs, HMEC-1) and TNBC cells (MDA-MB-231, HS578T). Tube formation assay was performed to detect angiogenesis. Compared with cancer cell conditioned medium (Ca-CM), the addition of ATP (ATP + Ca-CM) obviously promoted angiogenesis (Figure 1B). In addition, we found that 100 μM ATP-treated TNBC cells were more...
likely to adhere to ECs compared with non-ATP-treated TNBC cells (Figures 1C and S1C). These data suggested that ATP stimulated ECs migration, angiogenesis, and cancer cells’ adhesion to ECs.

3.2 Extracellular ATP upregulates CTGF expression in TNBC cells and ECs

We used cDNA microarray to identify differentially expressed genes in MCF-7 cells before and after 100 μM ATP treatment (accession number: GSE113757), furthermore, we applied RNA-seq to identify differentially expressed genes in co-cultured MCF-7 and fibroblast cells HFF1 before and after 100 μM ATP treatment. By GO analysis, we found that ATP significantly increased the expression of some genes related to migration and angiogenesis (Figure S2A). Among these genes, CTGF was related to both migration and angiogenesis and, as a secreted protein, CTGF was more able to explain the role of ATP from the angle of tumor microenvironment and cell–cell interaction. It is also worth noting that CTGF is an important protein in breast cancer. It is related to large tumor size, lymph node metastasis, and HER-2 status. Secreted CTGF could mediate the proliferation and migration of TNBC cells. This is why we chose CTGF for further study.

By immunohistochemical assay, we found that CTGF was expressed in tumor cells, fibroblasts, and ECs in human breast cancer tissues (Figure 1D). The expression of CTGF in breast cancer tissues was higher than in paired adjacent breast tissues (Figure S2B). To verify the cDNA microarray and RNA-seq data and further study the molecular mechanism, we performed qRT-PCR in BC cells, fibroblast cells, and ECs. We found that CTGF was upregulated upon ATP treatment in TNBC cells MDA-MB-231 and HS578T, as well as in ECs HMEC-1, and HUVECs (Figure 2A and Table S2). However, CTGF was not upregulated upon ATP treatment in normal breast epithelial cells MCF10A and non-TNBC cells SK-BR-3 and MCF-7 (Figure 2A and Table S2). Western blotting and ELISA assays verified the upregulation of CTGF protein upon ATP treatment in TNBC cells and ECs, and the upregulation was time dependent (Figure 2B, C).

3.3 CTGF is involved in ATP-driven migration and formation of pseudopodia in TNBC cells

To investigate the role of CTGF in ATP-driven migration, we inhibited its expression in TNBC cells and ECs using shRNAs against CTGF (Figure 2D and Figure S3A). Wound healing assays and transwell migration assays showed that ATP-enhanced migration could be attenuated by CTGF shRNAs in TNBC cells, and that this phenomenon could be rescued by rCTGF (Figure 2E and Figure S3B). Pseudopodia are actin-rich cellular protrusions facilitating the migration and metastasis of tumor cells. Immunofluorescence showed that TNBC cells formed more and longer pseudopodia upon ATP treatment, and CTGF shRNAs decreased the ATP-promoted formation of pseudopodia (Figure 2F).

We then examined the phosphorylation levels of focal adhesion kinase (FAK), which is closely related to BC cell migration and angiogenesis. Western blotting verified that ATP significantly increased pFAK (Y397) levels in TNBC cells, and that this phenomenon disappeared after knockdown of CTGF (Figure 2G). These results indicated that CTGF plays an important role in ATP-driven migration of TNBC cells.

3.4 CTGF is involved in ATP-driven migration of ECs and angiogenesis

Similarly, ATP-enhanced migration could be attenuated by CTGF shRNAs in ECs (Figures 3A and S3C), and this phenomenon could be rescued by recombinant CTGF protein (rCTGF). Spheroid sprouting assays and tube formation assays showed that ATP-enhanced sprouting (Figure 3B) and angiogenesis (Figure 3C) could be attenuated by CTGF shRNAs, and that this phenomenon could be rescued by rCTGF. ATP-induced phosphorylation of FAK (Y397) could also be attenuated by sh-CTGF (Figure 3D) in ECs. These results all indicated that CTGF plays an important role in ATP-driven EC migration and angiogenesis.

3.5 P2Y2-YAP signaling activation is involved in ATP-promoted upregulation of CTGF

Connective tissue growth factor has been reported to be regulated by TGFβ1 signaling and YAP signaling. KEGG analysis showed that both pathways were activated in HFF1 cells after ATP treatment (Figure S4A). Therefore, we examined whether ATP could activate the two signaling pathways in TNBC cells and ECs. qRT-PCR demonstrated that several downstream genes of YAP signaling were significantly upregulated in MDA-MB-231 and HUVECs (fold change > 2).
after ATP treatment (Figure S4B). Western blotting showed that extracellular ATP reduced the phosphorylation of YAP (S127) in TNBC cells and ECs (Figures 4A and S4C). It is reported that the dephosphorylated YAP protein can translocate from the cytoplasm to the nucleus and mediate transcription of downstream genes, including CTGF.\(^{30}\) We demonstrated the translocation of YAP from cytoplasm to nucleus upon ATP treatment using immunofluorescence staining (Figures 4B and S4D). Moreover, we found Peptide 17 (YAP-TEAD...
FIGURE 4 (Legend on next page)
inhibitor 1) could block ATP-induced CTGF upregulation in TNBC cells and ECs (Figures 4C and S4E). These data showed that YAP signaling was indeed involved in ATP-driven upregulation of CTGF.

We did not find activation of TGFB1 signaling upon ATP treatment (data not shown).

As P2 receptors are the preferred receptors for ATP and involved in ATP-mediated migration in cancer cells,25,31 we examined P2 subtypes in MDA-MB-231 and HUVECs. qRT-PCR showed that MDA-MB-231 and HUVECs predominantly expressed P2Y2 mRNA (Table S3). To study the role of P2Y2 in ATP-driven YAP signaling activation, we inhibited P2Y2 using its competitive receptor antagonist (AR-C 118925XX). Western blotting showed that ATP-enhanced YAP de-phosphorylation and CTGF upregulation could be blocked by AR-C 118925XX (Figures 4C,D and S4E). In addition, qRT-PCR showed that P2X4 inhibitor 5-BDBD and P2X7 inhibitor KN62 did not block ATP-induced CTGF upregulation (Figure S5A). These results showed that ATP-YAP-CTGF signaling was mediated by the P2Y2 receptor.

Furthermore, we demonstrated that ATP-enhanced migration and angiogenesis could be blocked by Peptide 17 (YAP-TEAD inhibitor 1) and AR-C 118925XX (P2Y2 antagonist) (Figure S5B,C), supporting the role of P2Y2-YAP signaling in ATP-driven migration and angiogenesis.

### 3.6 ATP–CTGF axis promotes TNBC cell adhesion to ECs through upregulation of integrin β1 in TNBC cells and VCAM-1 in ECs

Integrins are the main receptors of secreted CTGF and are closely related to the intercellular connection.32 We examined the expression of integrins by qRT-PCR, and found that mRNA expression of integrins αv, α5, αv, αv, and β1 in TNBC cells was dramatically upregulated upon ATP treatment (Figures 5A and S6A). However, only the upregulation of integrin β1 could be attenuated by CTGF shRNAs (Figures 5B and S6A). Western blotting verified the upregulation and activation of integrin β1 by ATP, which could also be attenuated by CTGF shRNAs (Figures 5C and S6B).

It is reported that integrin β1 in tumor cells interacted with a variety of ligands including fibronectin,33 zonula occludens-1 (ZO-1),34 angiopoietin-2,35 and vascular cell adhesion molecule-1 (VCAM-1).36 The interaction between integrin β1 and VCAM-1 mediated cellular adhesion, transmigration, and stimulated tumor cell metastasis.37 To find the ligand for integrin β1 in ECs, we tested VCAM-1 by qRT-PCR. Unexpectedly, VCAM-1 was upregulated by more than 10-fold in ECs upon ATP treatment, but this phenomenon disappeared after knockdown of CTGF (Figure 5D). To investigate how the ATP–CTGF axis regulated VCAM-1 expression in ECs, we tested the receptors of CTGF in ECs and found that the mRNA levels of integrin β1 were much higher than that of other CTGF receptors (Table S4). Integrin β1 has been reported to be able to activate the NF-κB signaling pathway,38,39 which is the main regulatory pathway for VCAM-1 expression.40 Therefore, our results suggested that ATP–CTGF regulates the expression of VCAM-1 in ECs through integrin β1.

To investigate the roles of CTGF, integrin β1 (TNBC cells), and VCAM-1 (ECs) in ATP-mediated adhesion of TNBC cells to ECs, shRNAs against integrin β1 and inhibitor to VCAM-1 (K-7174) were used in the following experiments (Figures 5E and S6C). We found that ATP-enhanced adhesion of TNBC cells to ECs was attenuated by CTGF shRNAs or integrin β1 shRNAs or K-7174 (Figures 5F and S6D). In addition, we found that ATP could promote tumor cell transmigration through the EC layer (Figures 5G and S6E), and that this phenomenon could be blocked by AR-C118925XX (P2Y2 inhibitor), CTGF shRNAs, integrin β1 shRNAs, and K-7174 (VCAM-1 inhibitor) (Figures 5G and S6E). These data indicated that extracellular ATP promoted TNBC cell adhesion to ECs and transmigration through the EC layer by activation of the P2Y2–CTGF–integrin β1 axis.

Integrin β1 and VCAM-1 often need integrin subunit αα or αα to interact with each other.41–43 We examined the two integrin subunits, and found that integrin αα was not expressed in MDA-MB-231 and that the expression of integrin αα was not upregulated by ATP (Figure 5A). However, ATP-enhanced adhesion and integrin β1-mediated adhesion of TNBC cells to ECs were both attenuated by integrin αα siRNAs (Figure S6F,G), indicating the involvement of integrin αα in this process.

### 3.7 ATP and CTGF promotes xenograft tumor metastasis and angiogenesis in vivo

Finally, we analyzed the effect of the ATP–CTGF axis on metastasis in vivo. BALB/c mice were injected into the mammary fat pad with six million Negative Control (NC) cells (defined as the NC group, n = 6), or NC cells followed by apyrase (an ATP hydrolase, 400 U/kg, intraperitoneal injection) treatment (defined as the NC + apyrase group, n = 6) or injected with sh-CTGF stably transfected MDA-MB-231 cells (defined as the sh-CTGF group, n = 6). Compared with NC inoculated tumors, NC + apyrase and sh-CTGF groups demonstrated a significant decrease in primary tumor volume (Figure 6A).
FIGURE 5 (Legend on next page)
Knockdown of CTGF by shRNA and intraperitoneal injections of apyrase both could dramatically inhibit lung and liver micrometastasis, and decrease the invasive ability into the neighboring tissues (Figure 6B), which indicated a less malignant phenotype. Western blotting and qRT-PCR showed that both NC + apyrase and sh-CTGF groups expressed lower levels of CTGF, nuclear YAP, pFAK, ITGB1, active ITGB1, and VCAM-1 than the NC group (Figure 6C,D). Immunohistochemical assay demonstrated the downregulation of tumor angiogenesis in both apyrase and sh-CTGF tumor tissues compared with the NC group (Figure 6E).

3.8 | The ATP–CTGF axis is associated with clinical breast cancer survival

Kaplan–Meier OS analyses for patients with BC (http://gepia.cancer-pku.cn/index.html) and TNBC (http://kmplot.com/analysis/) were performed. The results showed that high levels of CTGF and ITGB1 were associated with lower OS rates in BC patients (Figure 7A), as well as in TNBC patients (Figure 7B), although VCAM-1 was not significantly associated with OS. Through correlation analysis (https://xena.ucsc.edu/welcome-to-ucsc-xena/), we found that the expression levels of CTGF in breast cancer were positively correlated with vascular-related molecules (FGF1, FGF2, ANGPT1, ANGPT2, CD34, PECAM1) (Figure 7C). The GEPIA database showed that the expression levels of ITGB1 and VCAM-1 were positively correlated with CTGF in breast cancer (Figure 7D). These BC patients’ prognostic data supported our described experimental results.

4 | DISCUSSION

Extracellular ATP plays an important part in the tumor microenvironment. Under normal conditions, the extracellular ATP concentration ranges from 20 to 100 nm. When the cells in the tumor tissues are under conditions of ischemia and hypoxia, a large amount of intracellular ATP will be released, making the extracellular ATP concentration reach several hundred micromoles.\(^5\) In the 1990s, our laboratory demonstrated that extracellular ATP promoted the invasion of prostate cancer cells by activating PI3K/ATK and ERK1/2 signaling pathways.\(^7,31\) In further in-depth studies, we found that ATP could activate purine receptors P2Y2 and P2X7, then activate \(\beta\)-catenin and JAK1-STAT3-SOX9 signaling pathways and promote the invasion and metastasis of breast cancer cells.\(^24,25\)

Previous studies have mainly focused on the effect of extracellular ATP on tumor cells themselves, while various components in the tumor microenvironment, such as ECs, fibroblasts, and inflammatory cells, also play important roles in the process of tumor invasion and metastasis.\(^44,45\) Using function assays, we found that ATP could promote cell migration and angiogenesis. Using cDNA microarray and RNA-seq, we found that ATP could significantly increase the expression levels of multiple migration- and angiogenesis-related genes, which further confirmed this finding. Evgenia V Gerasimovskaya et al.\(^46\) found that extracellular ATP dramatically increased the rearrangement of isolated vasa vasorum ECs into tube-like networks on Matrigel, which supported our discovery. But the exact mechanism remains unclear. We found that CTGF expression was dramatically increased in TNBC cells and ECs after ATP treatment. Pai-Sheng Chen et al.\(^16\) found that CTGF enhances the motility of breast cancer cells via S100A4 upregulation. Wang LH et al.\(^23\) reported that CTGF could regulate angiogenesis in osteosarcoma through regulation of angiopoietin-2, which explained our findings. Accordingly, we also found that ANGPT2 in ECs was upregulated after ATP treatment (data not shown).

We found that the expression of CTGF was induced by ATP in only TNBC cells and ECs via P2Y2-YAP signaling, but not normal cells or non-TNBC cells. Lamar JM et al.\(^47\) reported that TAZ/YAP-TEAD complexes directly promoted the expression of CTGF. As a critical part of the complexes, nuclear TAZ was found to be conspicuously overexpressed in TNBC tissues, but not in other types of breast cancer tissues.\(^48\) Skibinski A et al. revealed that 44% of basal-like breast tumors exhibited some degree of TAZ copy-number amplification, compared with only 10% and 20% of luminal A and luminal B tumors, respectively. The high expression of TAZ in basal-like tumors is likely to result from copy-number amplification.\(^49\) The TNBC cells MDA-MB-231 and H5578T we used may also have TAZ copy-number amplification, which may be the possible reason for our findings.
FIGURE 6 (Legend on next page)
Integrins are the main receptors for CTGF. Downstream of the integrin pathways, FAK plays an important role in cell migration and angiogenesis promoted by CTGF. FAK has been reported to mediate keratinocyte and human chondrosarcoma cell migration through integrin $\alpha_{5}\beta_1$ and $\alpha_v\beta_3$, respectively. FAK was also reported to mediate angiogenesis in intrahepatic cholangiocarcinoma and gliomas through integrin $\alpha_v\beta_3$ and CD93–MMRN2–integrin $\beta_1$, respectively. All of these findings supported the function of FAK. In our study, we also found that FAK could be activated by ATP via CTGF.

In addition to promoting tumor angiogenesis, we found ATP could increase the adhesion of tumor cells to ECs and promote cancer cell
transmigration through the EC layer. Galina F et al.9 found that ATP plays important roles in polymorphonuclear (PMN) adhesion to ECs, supporting our findings. As the main receptors of secreted CTGF, integrins were also reported to be closely related to the intercellular connection.32 We then tested the expression of integrins in TNBC cells. We discovered that ATP upregulated the expression of integrin β1 by secreted CTGF in TNBC cells. Riley KG et al.54 found CTGF could upregulate integrin β1 expression in β-cells, which supported our discovery. The bioinformatics analysis in our study also supported our findings. We found that integrin β1 played an important role in ATP-driven TNBC cell adhesion to ECs and transmigration through the EC layer. More and more reports have shown that integrins facilitate cancer cell adhesion to ECs and tumor metastasis. ATN-161 (α5β1 inhibitor) was found to be able to diminish cancer metastases, reduce angiogenesis, and improve survival in a mouse model and human phase I trial.55,56

As integrin and cell adhesion were studied, we further detected the ligand of integrin β1, VCAM-1.57 We found that VCAM-1 in ECs was also upregulated by the ATP–CTGF axis. Rice GE et al.58 first reported the importance of VCAM-1 for melanoma adhesion to the endothelium. In addition to adhesion, VCAM-1 on ECs also mediates transendothelial migration of tumor cells.59,60 These reports supported our findings that upregulation of VCAM-1 by the ATP–CTGF axis participates in cancer cell adhesion to ECs and that TNBC cells transmigrate through the EC layer.

Our mouse model showed that both apyrase (an ATP hydrolyzing enzyme) and CTGF shRNAs could decrease angiogenesis and inhibit the metastasis of inoculated tumors. Morrone FB et al.61 reported that a rat glioma became less invasive and proliferative after apyrase treatment. Schumacher D et al.62 demonstrated that mice deficient in P2Y2 (ATP receptor) or lacking ATP secretion from platelets showed strongly reduced tumor metastasis. Hutchenerreuther J et al.21 found that mice deleted for CTGF in CAFs showed impaired vasculogenic mimicry of subcutaneously injected B16-F10 cells in vivo. All these reports supported our findings.

In summary, our study demonstrated that extracellular ATP promoted angiogenesis via upregulation of CTGF. In addition, ATP stimulated TNBC cell adhesion to ECs and transmigration through the EC layer via CTGF by upregulation of integrin β1 on TNBC cells and VCAM-1 on ECs (refer to the graphical abstract). The findings in this study have significant implications regarding our understanding of extracellular ATP in TNBC progression and metastasis. The pleiotropic effects of ATP in angiogenesis and cell adhesion suggested that extracellular ATP or CTGF could be an effective target for TNBC therapy.

ACKNOWLEDGMENTS
This work was supported by grants to Xin-Xia Tian and Wei-Gang Fang from the National Natural Science Foundation of China (Nos. 81872382, 81672790, and 81621063).

DISCLOSURE
The authors have no conflict of interest.

AUTHOR CONTRIBUTIONS
Yan-Ting Zhou designed the studies and wrote the manuscript. Yan-Ting Zhou, Yu-Qing Yu, and Hui Yang performed the experiments and analyzed data. Han Yang, Yan-Fei Huo, and Yang Huang helped with the experiments. Xin-Xia Tian and Wei-Gang Fang suggested experiments and revised the manuscript. All authors contributed to manuscript and reviewed and approved the manuscript.

ETHICAL APPROVAL
Approval of the research protocol by an Institutional Reviewer Board: The tissue microarrays for breast cancer patients were purchased from the National Human Genetic Resources Sharing Service Platform 2005DKA21300 (Shanghai Outdo Biotechnology Company Ltd., China). The research protocols were approved by the Ethics Committee of Shanghai Outdo Biotech Company (no. SHYJS-CP-1807025) and were conducted in accordance with the Declaration of Helsinki. Animal Studies: All procedures and protocols for animal studies were approved by the Institutional Animal Care and Use Committee of Peking University (no. LA2018190).

ORCID
Yan-Fei Huo https://orcid.org/0000-0001-5256-6936
Xin-Xia Tian https://orcid.org/0000-0002-1593-4987

REFERENCES
1. Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance. Oncologist. 2020;25(10):e1481-e1491.
2. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275-292.
3. Maishi N, Hida K. Tumor endothelial cells accelerate tumor metastasis. Cancer Sci. 2017;108(10):1921-1926.
4. Di Virgilio F, Sarti AC, Falzoni S, De Marchi E, Adinolfi E. Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. Nat Rev Cancer. 2018;18(10):601-618.
5. Roger S, Jelassi B, Couilln I, Pelegrin P, Besson P, Jiang LH. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochim Biophys Acta. 2015;1848(10):2584-2602.
6. von Kugelgen I, Harden TK. Molecular pharmacology, physiology, and structure of the P2Y receptors. Adv Pharmacol. 2011;61:373-415.
7. Chen L, He HY, Li HM, et al. ERK1/2 and p38 pathways are required for P2Y receptor-mediated prostate cancer invasion. Cancer Lett. 2004;215(2):239-247.
8. Kaczmarek E, Erb L, Koziak K, et al. Modulation of endothelial cell migration by extracellular nucleotides: involvement of focal adhesion kinase and phosphatidylinositol 3-kinase-mediated pathways. Thromb Haemost. 2005;93(4):735-742.
9. Sud’ina GF, Mirzoeva OK, Galkina SI, Pushkareva MA, Ulrich V. Involvement of ecto-ATPase and extracellular ATP in polymorphonuclear granulocyte-endothelial interactions. FEBS Lett. 1998;423(2):243-248.
10. Gomez Perdiguerio E, Liabotis-Fontugne A, Durand M, et al. ANGPTL4-α1-α2 interaction counteracts hypoxia-induced vascular permeability by modulating Src signalling downstream of vascular endothelial growth factor receptor 2. J Pathol. 2016;240(4):461-471.
11. Hsu YL, Hung JY, Chang WA, et al. Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1. Oncogene. 2017;36(34):4929-4942.

12. Yata T, Nishikawa M, Nishizaki C, et al. Control of hypoxia-induced tumor cell adhesion by cytophilic human catalase. Free Radic Biol Med. 2009;47(12):1772-1778.

13. Shen YW, Zhou YD, Chen HZ, Luan X, Zhang WD. Targeting CTGF in cancer: an emerging therapeutic opportunity. Trends Cancer. 2021;7(6):511-524.

14. Aikawa T, Gunn J, Spong SM, Klaus SJ, Korc M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol Cancer Ther. 2006;5(5):1108-1116.

15. Fuji M, Toyota T, Nakanishi H, et al. TGF-β synergizes with defects in the Hippo pathway to stimulate human malignant mesothelioma growth. J Exp Med. 2012;209(3):479-494.

16. Chen PS, Wang MY, Wu SN, et al. CTGF enhances the motility of breast cancer cells via an integrin-αlphaβ3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci. 2007;120(Pt 12):2053-2065.

17. Abreu JG, Kepurna NI, Reversade B, De Robertis EM. Connective tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol. 2002;4(8):599-604.

18. Jiang CG, Lv L, Liu FR, et al. Connective tissue growth factor is a positive regulator of epithelial-mesenchymal transition and promotes the adhesion with gastric cancer cells in human peritoneal mesothelial cells. Cytokine. 2013;61(1):173-180.

19. Yang K, Gao K, Hu G, Wen Y, Lin C, Li X. CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK/MEK/ERK signal pathway in colorectal cancer. Onco Targets Ther. 2016;9:7285-7295.

20. Xu X, Chen X, Xu M, et al. miR-375-3p suppresses tumorigenesis and partially reverses chemoresistance by targeting YAP1 and SP1 in colorectal cancer cells. Aging. 2019;11(18):7357-7385.

21. Hutchenerreuther J, Vincent K, Norley C, et al. Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma. Matrix Biol. 2018;74:52-61.

22. Liu SC, Chuang SM, Hsu CJ, Tsai CH, Wang SW, Tang CH. CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis. 2014;5:e1485.

23. Wang LH, Tsai HC, Cheng YC, et al. CTGF promotes osteosarcoma angiogenesis by regulating miR-543/angiopoietin 2 signaling. Cancer Lett. 2017;391:28-37.

24. Yang H, Geng YH, Wang P, et al. Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling. Oncogene. 2020;39(35):5795-5810.

25. Zhang JL, Liu Y, Yang H, Zhang HQ, Tian XX, Fang WG. ATP-P2Y2/beta-catenin axis prevents cells invasion in breast cancer cells. Cancer Sci. 2017;108(7):1318-1327.

26. Kim H, Son S, Ko Y, Shin I. CTGF regulates cell proliferation, migration, and glucose metabolism through activation of FAK signaling in triple-negative breast cancer. Oncogene. 2021;40(15):2667-2681.

27. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011;63(8):610-615.

28. Chen JQ, Guo YS, Chen Q, et al. TGFbeta1 and HGF regulate CTGF expression in human aortal fibroblasts and are involved in aortal remodeling in patients with rheumatic heart disease. J Cell Mol Med. 2019;23(4):3032-3039.

29. Sheih JM, Tsai YJ, Chi JC, Wu WB. TGFbeta mediates collagen production in human CRSNP nasal mucosa-derived fibroblasts through Smad2/3-dependent pathway and CTGF induction and secretion. J Cell Physiol. 2019;234(7):10489-10499.

30. Deng Q, Jiang G, Wu Y, et al. GPER/Hippo-YAP signal is involved in Bisphenol S induced migration of triple negative breast cancer (TNBC) cells. J Hazard Mater. 2018;355:1-9.

31. Li WH, Qiu Y, Zhang HQ, et al. P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer. 2013;109(6):1666-1675.

32. Lau LF. Cell surface receptors for CCN proteins. J Cell Commun Signal. 2016;10(2):121-127.

33. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533-548.

34. Tuomi S, Mai A, Nevo J, et al. PKCepsilon regulation of an alpha5 integrin-ZO-1 complex controls lamellae formation in migrating cancer cells. Sci Signal. 2009;2(77):ra32.

35. Hakanpaa L, Silpia T, Leppanen VM, et al. Endothelial destabilization by angiopioetin-2 via integrin beta1 activation. Nat Commun. 2015;6:5962.

36. Garyn-Susini B, Jin H, Zhu Y, Sung RJ, Hwang R, Varner J. Integrin alpha4beta1-VCAM-1-mediated adhesion between endothelial and mural cells is required for blood vessel maturation. J Clin Invest. 2005;115(6):1542-1551.

37. Li H, Ge C, Zhao F, et al. Hypoxia-inducible factor 1 alpha-activated angiopoietin-like protein 4 contributes to tumor metastasis via vascular endothelial cell adhesion molecule-1/integrin beta1 signaling in human hepatocellular carcinoma. Hepatology. 2011;54(3):910-919.

38. Yan L, He Z, Li W, Liu N, Gao S. P76RBE silencing inhibits ovarian cancer cell proliferation, migration, and invasion via suppressing the integrin β1/IFN-β signaling pathway. Cell Cycle. 2021;20(18):1875-1889.

39. Chen X, Lin J, Hu T, et al. Galectin-3 exacerbates ox-LDL-mediated endothelial injury by inducing inflammation via integrin β1-RhoA-JNK signaling activation. J Cell Physiol. 2019;234(7):10990-11000.

40. Lammel C, Zwichmaray J, Seigner J, Rollinger JM, de Martin R. Peucedanum ostruthium inhibits E-selectin and VCAM-1 expression in endothelial cells through interference with IFN-β signaling. Biomolecules. 2020;10(9):1215.

41. Chang AC, Chen PC, Lin YF, et al. Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin alpha4beta1 system. Cancer Lett. 2018:426:47-56.

42. Ross EA, Douglas MR, Wong SH, et al. Interaction between integrin alpha9beta1 and vascular cell adhesion molecule-1 (VCAM-1) inhibits its neutrophil apoptosis. Blood. 2006;107(3):1178-1183.

43. Allen MD, Vaziri R, Green M, et al. Clinical and functional significance of alpha9beta1 integrin expression in breast cancer: a novel cell-surface marker of the basal phenotype that promotes tumour cell invasion. J Pathol. 2011;223(5):646-658.

44. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF. Heterogeneity of the tumor vasculature. Semin Thromb Hemost. 2010;36(3):321-331.

45. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15(1):102-111.

46. Gerasimovskaya EV, Woodward HN, Tucker DA, Stenmark KR. Extracellular ATP is a pro-angiogenic factor for pulmonary artery vasa vorumendothelial cells. Angiogenesis. 2008;11(2):169-182.

47. Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA. 2012;109(37):E441-E4250.

48. Díaz-Martin J, López-García M, Romero-Pérez L, et al. Nuclear TAZ expression associates with the triple-negative phenotype in breast cancer. Endocr Relat Cancer. 2015;22(3):443-454.

49. Skibinski A, Breindel JL, Prat A, et al. The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. Cell Rep. 2014;6(6):1059-1072.

50. Kiwanuka E, Andersson L, Caterson EJ, Junker JP, Gerdin B, Eriksson E. CCN2 promotes keratinocyte adhesion and migration via integrin alpha5beta1. Exp Cell Res. 2013;319(19):2938-2946.
51. Tan TW, Lai CH, Huang CY, et al. CTGF enhances migration and MMP-13 upregulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. *J Cell Biochem*. 2009;107(2):345-356.

52. Yuan R, Li Y, Yang B, et al. LOXL1 exerts oncogenesis and stimulates angiogenesis through the LOXL1-FBLN5/alphavbeta3 integrin/FAK-MAPK axis in ICC. *Mol Ther Nucleic Acids*. 2021;23:797-810.

53. Lugano R, Vemuri K, Yu D, et al. CD93 promotes beta1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. *J Clin Invest*. 2018;128(8):3280-3297.

54. Riley KG, Pasek RC, Maulis MF, et al. Connective tissue growth factor modulates adult beta-cell maturity and proliferation to promote beta-cell regeneration in mice. *Diabetes*. 2015;64(4):1284-1298.

55. Stoeltzing O, Liu W, Reinmuth N, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. *Int J Cancer*. 2003;104(4):496-503.

56. Cianfrocca ME, Kimmel KA, Gallo J, et al. Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. *Br J Cancer*. 2006;94(11):1621-1626.

57. Sokeland G, Schumacher U. The functional role of integrins during intra- and extravasation within the metastatic cascade. *Mol Cancer*. 2019;18(1):12.

58. Rice GE, Bevilacqua MP. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. *Science*. 1989;246(4935):1303-1306.

59. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. *J Cell Physiol*. 2007;212(2):368-374.

60. Chan PY, Aruffo A. VLA-4 integrin mediates lymphocyte migration on the inducible endothelial cell ligand VCAM-1 and the extracellular matrix ligand fibronectin. *J Biol Chem*. 1993;268(33):24655-24664.

50. Morrone FB, Oliveira DL, Gamermann P, et al. In vivo glioblastoma growth is reduced by apyrase activity in a rat glioma model. *BMC Cancer*. 2006;6:226.

62. Schumacher D, Strllic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. *Cancer Cell*. 2013;24(1):130-137.

**SUPPORTING INFORMATION**

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Zhou Y-T, Yu Y-Q, Yang H, et al. Extracellular ATP promotes angiogenesis and adhesion of TNBC cells to endothelial cells via upregulation of CTGF. *Cancer Sci*. 2022;113:2457-2471. doi:10.1111/cas.15375